Progenitor cell secretory products exert additive renoprotective effects when combined with ace inhibitors in experimental CKD
Conclusions:
Early outgrowth cell-derived factors exert additive renoprotective effects on top of angiotensin-converting enzyme inhibitor therapy in experimental chronic kidney disease, providing the rationale for clinical trials of early outgrowth cell-based therapies for chronic kidney disease.
Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS - Category: Biomedical Science Authors: Kepecs, D. M., Yuen, D. A., Zhang, Y., Thai, K., Connelly, K. A., Gilbert, R. E. Tags: Original Article Source Type: research
More News: Biomedical Science | Chronic Kidney Disease | Clinical Trials | Enalapril | Nephrectomy | Proteinuria | Urology & Nephrology